ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $343,658,800 | +7.5% | 3,670,000 | +2.5% | 5.36% | +23.6% |
| Q2 2023 | $319,564,534 | -10.4% | 3,580,555 | +7.7% | 4.34% | -18.0% |
| Q1 2023 | $356,506,500 | -5.8% | 3,325,000 | +7.3% | 5.28% | -6.6% |
| Q4 2022 | $378,603,000 | +28.6% | 3,100,000 | +8.8% | 5.66% | +4.1% |
| Q3 2022 | $294,291,000 | +39.2% | 2,850,000 | +25.3% | 5.44% | +30.1% |
| Q2 2022 | $211,484,000 | -18.1% | 2,275,000 | +3.4% | 4.18% | -11.3% |
| Q1 2022 | $258,192,000 | -4.0% | 2,200,000 | +10.0% | 4.71% | +2.9% |
| Q4 2021 | $269,060,000 | -14.7% | 2,000,000 | +1.0% | 4.58% | -7.6% |
| Q3 2021 | $315,592,000 | +26.3% | 1,980,000 | +4.2% | 4.96% | +14.0% |
| Q2 2021 | $249,945,000 | -16.7% | 1,900,000 | +5.6% | 4.35% | -15.9% |
| Q4 2020 | $300,204,000 | +8.1% | 1,800,000 | 0.0% | 5.17% | +31.0% |
| Q3 2020 | $277,776,000 | +7.3% | 1,800,000 | +2.9% | 3.95% | -22.9% |
| Q2 2020 | $258,825,000 | +28.6% | 1,750,000 | -2.1% | 5.12% | -24.7% |
| Q1 2020 | $201,234,000 | -22.4% | 1,787,000 | -4.2% | 6.79% | -10.8% |
| Q4 2019 | $259,459,000 | +36.7% | 1,865,000 | -5.3% | 7.62% | -3.8% |
| Q3 2019 | $189,750,000 | -16.4% | 1,970,000 | 0.0% | 7.92% | +0.9% |
| Q2 2019 | $226,846,000 | +7.4% | 1,970,000 | +9.7% | 7.84% | -14.2% |
| Q1 2019 | $211,272,000 | +70.3% | 1,795,000 | -9.3% | 9.14% | +23.2% |
| Q4 2018 | $124,047,000 | -10.8% | 1,980,000 | +0.8% | 7.42% | +16.1% |
| Q3 2018 | $139,122,000 | +1.4% | 1,963,336 | -4.8% | 6.39% | +20.9% |
| Q2 2018 | $137,253,000 | +1.7% | 2,063,336 | 0.0% | 5.28% | -18.0% |
| Q1 2018 | $134,942,000 | +100.4% | 2,063,336 | +22.7% | 6.44% | +47.6% |
| Q4 2017 | $67,342,000 | +13.5% | 1,681,024 | +2.7% | 4.36% | -5.1% |
| Q3 2017 | $59,309,000 | +115.6% | 1,636,124 | +65.1% | 4.60% | +32.5% |
| Q2 2017 | $27,508,000 | +40.2% | 990,924 | +41.4% | 3.47% | +38.5% |
| Q1 2017 | $19,626,000 | +77.9% | 700,924 | +28.6% | 2.51% | +12.5% |
| Q4 2016 | $11,035,000 | +1114.0% | 545,203 | +1106.1% | 2.23% | +1301.9% |
| Q3 2016 | $909,000 | – | 45,203 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |